{"id":965478,"date":"2026-05-20T17:37:44","date_gmt":"2026-05-20T21:37:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/"},"modified":"2026-05-20T17:37:44","modified_gmt":"2026-05-20T21:37:44","slug":"eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/","title":{"rendered":"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress"},"content":{"rendered":"

\nConference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET
\n<\/h2>\n
\n

IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study.<\/p>\n

Details on the presentations are below:<\/p>\n

\n Oral Presentation<\/u>\n <\/p>\n

\n Title:<\/strong> Phase 2 BESTOW Trial: Evaluating Tegoprubart\u2019s Safety and Efficacy in Preventing Kidney Transplant Rejection<\/p>\n

\n Presenter: <\/strong>Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview<\/p>\n

\n Abstract Publication Number: <\/strong>585<\/p>\n

\n Session Title: <\/strong>Emerging Discoveries Oral Abstract Session – Kidney: Biomarkers -3<\/p>\n

\n Session Date and Time:<\/strong> Monday, June 22, 2026, from 11:15 a.m. – 12:15 p.m. ET<\/p>\n

\n Session Room: <\/strong>253BC (Level 2)<\/p>\n

\n Presentation Time:<\/strong> 12:03 p.m. \u2013 12:15 p.m. ET<\/p>\n

\n Poster Presentation<\/u>\n <\/p>\n

\n Title:<\/strong> Phase 2 BESTOW Extension Trial Evaluating Tegoprubart\u2019s Long-Term Safety and Efficacy in Preventing Kidney Transplant Rejection<\/p>\n

\n Session Date and Time:<\/strong> Saturday, June 20, 2026, from 5:45 p.m. – 6:45 p.m. ET<\/p>\n

Following the conference, a copy of the oral and poster presentation will be available in the Investors section of the Company\u2019s website at\u00a0https:\/\/ir.eledon.com\/news-and-events\/publications-and-presentations<\/a>.<\/p>\n

\n Conference Call<\/strong>\n <\/p>\n

Eledon will hold a conference call on June 22, 2026 at 8:00 a.m. Eastern Time to discuss updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study presented at the American Transplant Congress. The dial-in numbers are 1-800-717-1738 for domestic callers and 1-646-307-1865 for international callers. The conference ID is 84665. A live webcast of the conference call will be available on the Investor Relations section of the Company’s website at www.eledon.com. The webcast will be archived on the website following the completion of the call.<\/p>\n

\n About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart<\/strong>\n <\/p>\n

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company\u2019s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company\u2019s website at www.eledon.com.<\/p>\n

Follow\u00a0Eledon Pharmaceuticals\u00a0on social media:\u00a0LinkedIn<\/a>;\u00a0X<\/a><\/p>\n

\n Investor Contact:<\/strong>\n <\/p>\n

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com<\/a><\/p>\n

\n Media Contact:<\/strong>\n <\/p>\n

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com<\/a><\/p>\n

Source:\u00a0Eledon Pharmaceuticals<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart\u2019s Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: … <\/p>\n

Continue reading “Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-965478","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart\u2019s Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: … Continue reading "Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T21:37:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress\",\"datePublished\":\"2026-05-20T21:37:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/\"},\"wordCount\":540,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/\",\"name\":\"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA=\",\"datePublished\":\"2026-05-20T21:37:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/","og_locale":"en_US","og_type":"article","og_title":"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress - Market Newsdesk","og_description":"Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart\u2019s Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: … Continue reading \"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-20T21:37:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress","datePublished":"2026-05-20T21:37:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/"},"wordCount":540,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/","name":"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA=","datePublished":"2026-05-20T21:37:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDE3NiM3NjE0MzQzIzIwMDY1NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-present-new-long-term-data-from-phase-2-bestow-trial-of-tegoprubart-for-the-prevention-of-rejection-in-kidney-transplantation-at-american-transplant-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=965478"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965478\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=965478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=965478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=965478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}